DBV Technologies (DBVT) Other Non-Current Liabilities (2014 - 2025)
DBV Technologies (DBVT) reported Other Non-Current Liabilities of $8.4 million for Q3 2025, up 8.52% year-over-year from $7.8 million in Q3 2024, and up 12.38% on a QoQ basis from $7.5 million in Q2 2025.
DBV Technologies (DBVT) has 12 years of Other Non-Current Liabilities data on file, last reported at $8.4 million in Q3 2025.
- Quarterly Other Non-Current Liabilities rose 8.52% year-over-year to $8.4 million in Q3 2025, while the trailing twelve-month figure through Sep 2025 was $8.4 million (up 8.52% YoY) and the FY2024 annual result came in at $8.3 million, down 6.78% from the prior year.
- Other Non-Current Liabilities rose to $8.4 million in Q3 2025 per DBVT's latest filing, from $7.5 million in the prior quarter.
- Across five years, Other Non-Current Liabilities topped out at $17.0 million in Q3 2021 and bottomed at $979000.0 in Q3 2022.
- The 5-year median for Other Non-Current Liabilities is $5.2 million (2024), against an average of $6.2 million.
- The widest annual swing landed in 2021, when Other Non-Current Liabilities jumped 652.09%; it then plunged 94.22% in 2022.
- Tracing DBVT's Other Non-Current Liabilities over 5 years: stood at $2.1 million in 2021, then soared by 120.54% to $4.7 million in 2022, then soared by 88.68% to $8.9 million in 2023, then fell by 6.78% to $8.3 million in 2024, then grew by 1.45% to $8.4 million in 2025.
- Per Business Quant, the three latest DBVT Other Non-Current Liabilities figures stand at $8.4 million (Q3 2025), $7.5 million (Q2 2025), and $5.4 million (Q1 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | DBV Technologies | 8.00 Bn | 7.77 Bn | -3.90 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | 8.45 Mn |
| Jun 30, 2025 | 7.52 Mn |
| Mar 31, 2025 | 5.45 Mn |
| Dec 31, 2024 | 8.33 Mn |
| Sep 30, 2024 | 7.79 Mn |
| Mar 31, 2024 | 5.02 Mn |
| Dec 31, 2023 | 8.93 Mn |
| Sep 30, 2023 | 2.70 Mn |
| Jun 30, 2023 | 11.25 Mn |
| Mar 31, 2023 | 4.39 Mn |
| Dec 31, 2022 | 4.74 Mn |
| Sep 30, 2022 | 979,000.00 |
| Jun 30, 2022 | 10.54 Mn |
| Mar 31, 2022 | 1.46 Mn |
| Dec 31, 2021 | 2.15 Mn |
| Sep 30, 2021 | 16.95 Mn |
| Jun 30, 2021 | 3.47 Mn |
| Mar 31, 2021 | 1.29 Mn |
| Dec 31, 2020 | 475,000.00 |
| Jun 30, 2020 | 461,511.79 |
| Dec 31, 2019 | 78,589.02 |
| Sep 30, 2019 | 1.16 Mn |
| Jun 30, 2019 | 1.82 Mn |
| Dec 31, 2018 | 4.69 Mn |
| Jun 30, 2018 | 8.95 Mn |
| Dec 31, 2017 | 1.48 Mn |
| Jun 30, 2017 | 10.04 Mn |
| Dec 31, 2016 | 921,004.76 |
| Jun 30, 2016 | 9.00 Mn |
| Dec 31, 2015 | 537,097.47 |
| Jun 30, 2015 | 808,156.66 |
| Dec 31, 2014 | 663,661.58 |